Anumana's parent company, nference, announces strategic partnership with Duke Health

See Release

Unlocking the language of the heart

Harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to improve patient care throughout the cardiac clinical pathway

divider

Anumana is a new AI-driven health technology company from nference, developing and delivering algorithms and AI-enabled software for a broad range of cardiac applications with practical and workflow-integrated clinical decision support tools for better patient care

Our Impact

The Impact of AI Algorithms in Cardiology

Listen to Dr. Paul Friedman, a Professor of Medicine and Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Anumana advisor, discuss the potential of AI algorithms in advancing early diagnosis and intervention in cardiology.

Diagnostic Electrocardiography

Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate. Unfortunately, these conditions can remain undiagnosed until the patient suffers a life-threatening event. Hidden and undiagnosed cardiovascular diseases can often be treated through available therapeutics and medical devices. Innovations enabling earlier diagnoses could address this unmet medical need and empower healthcare providers to intervene with beneficial treatments.

Interventional Electrophysiology

Millions of people suffer from cardiac arrhythmias, which can be a major risk of stroke and heart failure. The demand for electrophysiology (EP) procedures has been increasing rapidly but efficacy largely depends on experience and intuition, and repeat procedures are common. While large amounts of data are generated in real- time during the procedure, EP labs so far have not leveraged the power of AI interpretation. Deep-learning innovations could enable improved EP procedure accuracy and reduced procedure time, empowering providers to meet the growing demand with improved patient safety and outcomes.

divider

Why Us

Rich Data & Industry-Leading Technology
Rich Data & Industry-Leading Technology

Anumana leverages nference’s proprietary nSights real-world evidence generation platform, built on data from leading health systems, to combine unparalleled longitudinal structured and unstructured electronic medical record data with diagnostic and interventional ECGs and EGMs. By applying AI techniques to these electrical signals from the heart, the company has uncovered clinically critical electrical signatures and patterns unrecognizable to the human eye. The resulting software products can be integrated into routine clinical practice for earlier disease diagnosis and in-procedure decision making.

AI Solutions Spanning the Cardiac Care Continuum
AI Solutions Spanning the Cardiac Care Continuum

With a leading position in developing AI-enabled ECG algorithms, Anumana’s acquisition of NeuTrace in 2022 paved the way for a combined development capability in cardiac electrophysiology spanning the entire cardiac care continuum, from disease detection to in-procedure, interventional solutions.

Clinical Workflow Solutions to Improve Decision-Making
Clinical Workflow Solutions to Improve Decision-Making

Today, Anumana’s research is demonstrating that care teams working with AI-enabled tools can diagnose otherwise hidden conditions earlier than ever before and uncover actionable insights to potentially improve EP procedures. With clinical decision support tools, Anumana aims to help physicians identify missing treatments and avoid unnecessary interventions. Anumana is committed to bringing these software solutions to routine clinical practice with significant progress in software development and coding for reimbursement.

The Tech Tribune
Fierce Biotech
Bostinno
MedCity News
Pulmonary Hypertension News
DAIC
Modern Healthcare
Becker's Hospital Review
Medical Press
Mass Device

Diagnostic Algorithm Pipeline

Innovative diagnostic tools for detecting rare and hidden disease, based on the world’s largest labeled patient dataset, built to be integrated into existing physician workflows and currently pursuing FDA approval.

Program
Development
Pre-Submission
Validation
Submission
Market Authorization
Low Ejection Fraction
Novartis

Granted FDA Breakthrough Device Designation

Phase: Validation

Pulmonary Hypertension

Granted FDA Breakthrough Device Designation

Phase: Pre-Submission

Hyperkalemia

Granted FDA Breakthrough Device Designation

Phase: Development

Cardiac Amyloidosis

Phase: Development

Atrial Fibrillation in Normal Sinus Rhythm

Phase: Development

Hypertrophic Cardiomyopathy

Phase: Development

Myocarditis

Phase: Development

Aortic Stenosis

Phase: Development

Early Stage Development Programs

Phase: Development

Interventional EP Product Pipeline

Anumana also has a rich pipeline of AI / ML driven products for use in the interventional electrophysiology (EP) setting.

Program
Development
Pre-Submission
Validation
Submission
Authorization
Hardware Agnostic AI / ML based EAM Software

Phase: Authorization

EP Case Review Software

FDA Clearance Not Required

Phase: Submission

Signal Identification Software

Phase: Validation

Early Stage Development Programs

Phase: Development

divider

In the Media

Quotes

At Mayo Clinic, AI engineers face an ‘acid test’: Will their algorithms help...

In just the past three years, the team has published more than two dozen studies on AI in cardiology, and it is now field-testing an algorithm to detect a weak heart pump in dozens of primary care clinics.

Stat

Dec. 18th, 2019

Partner with us!

We’re actively developing algorithms for FDA approval. Please direct partnership and media inquiries to hello@anumana.ai